Amgen Restructures Amid Anemic Aranesp Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech will eliminate up to 2,600 jobs, prioritize R&D spend to achieve $1 billion to $1.3 billion in pre-tax savings.
You may also be interested in...
Aranesp Takes A Punch; Sales Plummet 25 Percent In Fourth Quarter 2007
With ESA safety in the spotlight, Amgen faced its toughest year, CEO Sharer says.
Aranesp Takes A Punch; Sales Plummet 25 Percent In Fourth Quarter 2007
With ESA safety in the spotlight, Amgen faced its toughest year, CEO Sharer says.
Amgen Says 2007 Profits Will Top October Projections
California biotech cites cost-cutting measures as reason for upgraded earnings per share guidance of $4.30.